138 related articles for article (PubMed ID: 21617728)
1. Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedin.
Grosso F; D'Incalci M
Tumori; 2011; 97(2):256. PubMed ID: 21617728
[No Abstract] [Full Text] [Related]
2. Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity.
Stoyianni A; Kapodistrias N; Kampletsas E; Pentheroudakis G; Pavlidis N
Tumori; 2011; 97(2):252-5. PubMed ID: 21617727
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
Golomb B; Evans M
Drug Saf; 2006; 29(12):1191; author reply 1191-2. PubMed ID: 17147465
[No Abstract] [Full Text] [Related]
4. [Rhabdomyolysis following the coprescription of atorvastatin and fusidic acid].
Gabignon C; Zeller V; Le Guyader N; Desplaces N; Lidove O; Ziza JM
Rev Med Interne; 2013 Jan; 34(1):39-41. PubMed ID: 23102978
[TBL] [Abstract][Full Text] [Related]
5. [Rhabdomyolysis associated to combined ezetimibe-statin treatment].
Piedra León M; García Unzueta MT; Otero Martínez M; Amado Señaris JA
Rev Clin Esp; 2007 Sep; 207(8):425-6. PubMed ID: 17688879
[No Abstract] [Full Text] [Related]
6. Intensive lipid lowering with atorvastatin in coronary disease.
Ravnskov U; Rosch PJ; Sutter MC
N Engl J Med; 2005 Jul; 353(1):93-6; author reply 93-6. PubMed ID: 16003834
[No Abstract] [Full Text] [Related]
7. Hypernatremia due to rhabdomyolysis in a patient on statin.
Victor SM; Gnanaraj A; Abraham G; Sankardas MA
Saudi J Kidney Dis Transpl; 2011 Sep; 22(5):1037-8. PubMed ID: 21912045
[No Abstract] [Full Text] [Related]
8. Statin-induced rhabdomyolysis and dermatomyositis: a rare combination.
Cannon CS
JAAPA; 2012 Aug; 25(8):30, 32-3. PubMed ID: 22928274
[No Abstract] [Full Text] [Related]
9. Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma.
Skorupa A; Beldner M; Kraft A; Montero AJ
Cancer Biol Ther; 2007 Jul; 6(7):1015-7. PubMed ID: 17611408
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD; von Mehren M; Jones RL; Hensley ML; Schuetze SM; Staddon A; Milhem M; Elias A; Ganjoo K; Tawbi H; Van Tine BA; Spira A; Dean A; Khokhar NZ; Park YC; Knoblauch RE; Parekh TV; Maki RG; Patel SR
J Clin Oncol; 2016 Mar; 34(8):786-93. PubMed ID: 26371143
[TBL] [Abstract][Full Text] [Related]
11. Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.
Theman TA; Hartzell TL; Sinha I; Polson K; Morgan J; Demetri GD; Orgill DP; George S
J Clin Oncol; 2009 Nov; 27(33):e198-200. PubMed ID: 19805684
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A
J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065
[TBL] [Abstract][Full Text] [Related]
13. Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
Tewari D; Saffari B; Cowan C; Wallick AC; Koontz MZ; Monk BJ
Gynecol Oncol; 2006 Sep; 102(3):421-4. PubMed ID: 16797679
[TBL] [Abstract][Full Text] [Related]
14. Statin-associated rhabdomyolysis: is there a dose-response relationship?
Holbrook A; Wright M; Sung M; Ribic C; Baker S
Can J Cardiol; 2011; 27(2):146-51. PubMed ID: 21459261
[TBL] [Abstract][Full Text] [Related]
15. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine.
Castro JG; Gutierrez L
Am J Med; 2002 Apr; 112(6):505. PubMed ID: 11959068
[No Abstract] [Full Text] [Related]
16. [Rhabdomyolysis after treatment with atorvastatin detected by bone scintigraphy].
Rubí S; Duch J; Ortín J; Setoain X; Pons F
Rev Esp Med Nucl; 2006; 25(6):393. PubMed ID: 17173790
[No Abstract] [Full Text] [Related]
17. Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects.
Prescrire Int; 2009 Aug; 18(102):161. PubMed ID: 19743575
[No Abstract] [Full Text] [Related]
18. Tachyphylaxis and statin drugs.
Stein JH; McBride PE
Am J Cardiol; 2001 Mar; 87(5):674. PubMed ID: 11245286
[No Abstract] [Full Text] [Related]
19. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.
Le Cesne A; Yovine A; Blay JY; Delaloge S; Maki RG; Misset JL; Frontelo P; Nieto A; Jiao JJ; Demetri GD
Invest New Drugs; 2012 Jun; 30(3):1193-202. PubMed ID: 21484250
[TBL] [Abstract][Full Text] [Related]
20. Rhabdomyolysis with atorvastatin and fusidic acid.
O'Mahony C; Campbell VL; Al-Khayatt MS; Brull DJ
Postgrad Med J; 2008 Jun; 84(992):325-7. PubMed ID: 18644925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
